Sernova (SVA) AI Stock Analysis

• Market Cap: C$48.82M
• Dividend Yield: N/A
• Average Volume (3M): 125.66K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: N/A
• EPS Growth: 54.38%
• Country: CA
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 336,698,550
• 10 Day Avg. Volume: 126,270
• 30 Day Avg. Volume: 125,661
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.12 ▼(-19.33% Downside)

The score is held back primarily by weak financial fundamentals (pre-revenue losses, negative equity, higher debt, and ongoing funding needs). Technicals are also bearish with the price below key moving averages, partially offset by oversold signals. Corporate events provide a modest uplift due to financing and debt-to-equity conversion, while valuation remains constrained by ongoing losses and no dividend.

Positive Factors

Clinical Advancements

Securing funding for clinical advancements in diabetes treatment positions Sernova as a leader in innovative therapies, potentially enhancing long-term growth prospects.

FDA Clearance

FDA clearance for thyroid cell therapy trial strengthens Sernova's market position in regenerative medicine, paving the way for new treatment solutions and potential revenue streams.

Leadership Enhancement

The addition of an experienced Chief Development Officer enhances Sernova's R&D capabilities, potentially accelerating product development and improving strategic execution.

Negative Factors

Financial Distress

The absence of revenue and negative equity indicate significant financial distress, limiting Sernova's ability to sustain operations and invest in growth without external funding.

Negative Cash Flow

Persistent negative cash flow highlights liquidity issues, increasing dependence on external financing and potentially constraining future operational flexibility.

Mounting Losses

Rising net losses reflect operational challenges and an unprofitable core business, posing risks to long-term viability and necessitating strategic changes for improvement.

Sernova Business Overview & Revenue Model

Company Description

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

How the Company Makes Money

Sernova primarily generates revenue through the development and potential commercialization of its Cell Pouch System and associated therapeutic cells. The company could earn income through licensing agreements, partnerships, and collaborations with other biotech or pharmaceutical companies interested in integrating Sernova's technology into their treatment pipelines. Additionally, Sernova may receive milestone payments and royalties from these partners as their therapeutics progress through clinical trials and toward market approval. The company may also benefit from research grants and government funding to support its innovation and development efforts.

Sernova Financial Statement Overview

Summary

Sernova faces severe financial challenges with no revenue generation, mounting losses, and negative equity. The company's financial health is concerning, suggesting a high-risk profile without significant operational or strategic changes.

Income Statement

The company reports zero revenue with consistently increasing net losses over the years, indicating significant operational challenges. Gross profit and EBITDA are also negative, reflecting an unprofitable core business.

Balance Sheet

The company has negative stockholders' equity in the latest period, indicating financial distress. The debt-to-equity ratio is not meaningful due to negative equity, and total liabilities exceed total assets, highlighting significant leverage and risk.

Cash Flow

Operating cash flows are consistently negative, showing reliance on external financing for operations. Free cash flow is also negative, with recent financing inflows not enough to cover operational cash burn. This signals potential liquidity issues.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-342.59K	0.00	-445.55K	-440.00K	-267.20K
EBITDA	-14.74M	-31.25M	-40.19M	-24.54M	-6.60M
Net Income	-15.74M	-32.19M	-39.00M	-24.54M	-7.02M
Balance Sheet
Total Assets	764.23K	7.53M	22.11M	52.48M	29.82M
Cash, Cash Equivalents and Short-Term Investments	265.00K	6.01M	19.81M	49.78M	27.87M
Total Debt	17.28M	569.94K	136.12K	275.98K	393.35K
Total Liabilities	25.84M	20.48M	9.59M	4.88M	1.75M
Stockholders Equity	-25.08M	-12.96M	12.51M	47.61M	28.07M
Cash Flow
Free Cash Flow	-10.91M	-18.90M	-30.44M	-14.75M	-6.86M
Operating Cash Flow	-10.91M	-18.90M	-30.34M	-14.42M	-6.84M
Investing Cash Flow	24.96K	11.12M	34.78M	-46.34M	-228.78K
Financing Cash Flow	5.14M	5.07M	503.46K	36.66M	31.00M

Sernova Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.15
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SVA, the sentiment is Neutral. The current price of 0.15 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.14, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.34 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:SVA.

Sernova Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	53 Neutral	C$47.71M	23.17	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	49 Neutral	C$33.31M	-15.19	-8.01%	―	-26.81%	-161.24%
DTC	45 Neutral	C$32.84M	-8.90	―	―	―	72.92%
SVA	44 Neutral	C$48.82M	-3.13	―	―	―	54.38%
MIR	42 Neutral	C$48.84M	-12.07	―	―	-41.70%	-35.42%

Sernova Corporate Events

Sernova Biotherapeutics Advances Diabetes Treatment with New Funding

Sernova Biotherapeutics has successfully closed the first tranche of a private placement, raising CAD $874,600 to advance its clinical program for type 1 diabetes. The funds will support the launch of Cohort C in its ongoing Phase 1/2 clinical trial, which will incorporate the novel immunomodulatory antibody tegoprubart, expected to improve clinical outcomes. This financing, along with anticipated future tranches and a conversion of legacy debt to equity, strengthens Sernova’s financial position as it progresses towards a functional cure for insulin-dependent diabetes.

The most recent analyst rating on (TSE:SVA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Sernova stock, see the TSE:SVA Stock Forecast page.